Beregnet på helsepersonell

Skriv ut siden
Referanser

 

1. Preparatomtalen for Lyrica. Sist godkjent September 06.

2. Sabatowski R et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with PHN. Pain 109;2002:89-97

3. Dworkin RH et al. Pregabalin for the treatment og PHN. A randomized, placebo-controlled trial. Neurology 2003;60:1274-1283

4. Van Seventer et al. J Pain 2004;5 Suppl. 1:58

5. Ricther et al. Relief of painful DPN with pregabalin: A randomized, placebo controlled study, T J Pain 2005;6(4):253-260

6. Lesser et al. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized, controlled trial. Neurology 2004;63:2104-10

7. Rosenstock et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebocontrolled trial. Pain 110(2004)628-38

8. Pohl et al. Efficacy of pregabalin in the treatment of generalized anxiety disorder. J Clin Psychopharmacol.

9. Brodie et al. Pregabalin as adjunctive therapy for partial seizures. Epilepsia 2004;45 Suppl.6:19-27

10.  French et al. Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology 2003;60:1631-37

11. Fink et al. Neuropharmacology 2002;42:229-36

12. Maneuf et al. Pain 2001;93(2):191-6

13.  Dooley et al. Jour of Pharmacology and Experimental Therapeutics 2000;295:1086-93

14.  Framtpon et al. Pregabalin in the treatment of postherpetic neuralgia. Drugs 2005;65(1):111-8

15.  Framtpon et al. Pregabalin in the treatment of painful diabetic peripheral neuropathy. Drugs 2004;64(24):2813-20

16.  Montgomery et al. The efficacy and safety of pregabalin in the treatment of generalized anxiety disorder. J Clin Psychiatry

17.  Retningslinjer for smertebehandling i Norge. Godkjent av den norske lægeforenings sentralstyre. 28.10.2003

18.   Kessler RC et al. Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in national surveys. Am J Psychiatry 1999;156:1915-1923

19.   Wittchen HU et al. Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey. Int Clin Psychopharmacol 2000;15:319-328

 

Sist oppdatert 7. sept. '09


Pfizer AS, Postboks 3, 1324 Lysaker | Tlf: 67 52 61 00 Faks: 67 52 61 99| Behandling av personopplysninger | Informasjon om cookies